Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...

Persistent Corneal Epithelial Defects (PCEDs) occur when the corneal epithelium fails to re-epithelialize and close within 10-14 days following an injury, despite standard treatment.

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PI ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Amgen (AMGN) announced on Monday that a late-stage study evaluating its Bemarituzumab in combination with chemotherapy met ...

Corneal ulcer occurs in 10% of the population of VKC patients. If left untreated, a plaque containing fibrin and mucus is deposited over the epithelial defect.